Indirubin shows anti-angiogenic activity in an in vivo zebrafish model and an in vitro HUVEC model

Journal of Ethnopharmacology

Volumn 131, Issue 2, 2010, Pages 242-247

  Alex, Deepa ^a   Lam, In Kei ^a   Lin, ZhiXiu ^b   Lee, Simon Ming Yuen ^a  

^a University of Macau   (Macao)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Anti angiogenesis; Apoptosis; Indirubin; Zebrafish

Indexed keywords

INDIRUBIN; VASCULOTROPIN INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL CYCLE ARREST; CELL DEATH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; EMBRYO; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NICK END LABELING; NONHUMAN; ZEBRA FISH;

DANIO RERIO;

EID: 77956268307     PISSN: 03788741     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jep.2010.05.016     Document Type: Article

References (30)

1. Abe R., Yamagishi S.I., Fujita Y., Hoshina D., Sasaki M., Nakamura K., Matsui T., Shimizu T., Bucala R., Shimizu H. Topical application of anti-angiogenic peptides based on pigment epithelium-derived factor can improve psoriasis. Journal of Dermatological Science 2010, 57:183-191.
2. Alex D., Leong E.C., Zhang Z.J., Yan G.T., Cheng S.H., Leong C.W., Li Z.H., Lam K.H., Chan S.W., Lee S.M. Resveratrol derivative, trans-3,5,4'-trimethoxystilbene, exerts antiangiogenic and vascular-disrupting effects in zebrafish through the downregulation of VEGFR2 and cell-cycle modulation. Journal of Cellular Biochemistry 2010, 109:339-346.
3. Cross M.J, Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends in Pharmacological Sciences 2001, 22:201-207.
4. Ding G.S. Important Chinese herbal remedies. Clinical Therapeutics 1987, 9:345-357.
5. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nature Medicine 1995, 1:27-31.
6. Grant K.M., Dunion M.H., Yardley V., Skaltsounis A.L., Marko D., Eisenbrand G., Croft S.L., Meijer L., Mottram J.C. Inhibitors of Leishmania mexicana CRK3 cyclin-dependent kinase: chemical library screen and antileishmanial activity. Antimicrobial Agents and Chemotherapy 2004, 48:3033-3042.
7. Han R. Highlight on the studies of anticancer drugs derived from plants in China. Stem Cells 1994, 12:53-63.
8. Heidenreich R., Rocken M., Ghoreschi K. Angiogenesis drives psoriasis pathogenesis. International Journal of Experimental Pathology 2009, 90:232-248.
9. Hoessel R., Leclerc S., Endicott J.A., Nobel M.E., Lawrie A., Tunnah P., Leost M., Damiens E., Marie D., Marko D., Niederberger E., Tang W., Eisenbrand G., Meijer L. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nature Cell Biology 1999, 1:60-67.
10. Hong S.J., Wan J.B., Zhang Y., Hu G., Lin H.C., Seto S.W., Kwan Y.W., Lin Z.X., Wang Y.T., Lee S.M. Angiogenic effect of saponin extract from Panax notoginseng on HUVECs in vitro and zebrafish in vivo. Phytotherapy Research 2009, 23:677-686.
11. Jackson J.R., Seed M.P., Kircher C.H., Willoughby D.A., Winkler J.D. The codependence of angiogenesis and chronic inflammation. The FASEB Journal 1997, 11:457-465.
12. Kameswaran T.R., Ramanibai R. Indirubin-3-monooxime induced cell cycle arrest and apoptosis in Hep-2 human laryngeal carcinoma cells. Biomedicine and Pharmacotherapy 2009, 63:146-154.
13. Knockaert M., Blondel M., Bach S., Leost M., Elbi C., Hager G.L., Nagy S.R., Han D., Denison M., Ffrench M., Ryan X.P., Magiatis P., Polychronopoulos P., Greengard P., Skaltsounis L., Meijer L. Independent actions on cyclin-dependent kinases and aryl hydrocarbon receptor mediate the antiproliferative effects of indirubins. Oncogene 2004, 23:4400-4412.
14. Kunikata T., Tatefuji T., Aga H., Iwaki K., Ikeda M., Kurimoto M. Indirubin inhibits inflammatory reactions in delayed-type hypersensitivity. European Journal of Pharmacology 2000, 410:93-100.
15. Lam H.W., Lin H.C., Lao S.C., Gao J.L., Hong S.J., Leong C.W., Yue P.Y., Kwan Y.W., Leung A.Y., Wang Y.T., Lee S.M. The angiogenic effects of Angelica sinensis extract on HUVEC in vitro and zebrafish in vivo. Journal of Cellular Biochemistry 2008, 103:195-211.
16. Langheinrich U. Zebrafish: a new model on the pharmaceutical catwalk. Bioessays 2003, 25:904-912.
17. Lawson N.D., Weinstein B.M. In vivo imaging of embryonic vascular development using transgenic zebrafish. Developmental Biology 2002, 248:307-318.
18. Leclerc S., Garnier M., Hoessel R., Marko D., Bibb J.A., Snyder G.L., Greengard P., Biernat J., Wu Y.Z., Mandelkow E.M., Eisenbrand G., Meijer L. Indirubins inhibit glycogen synthase kinase-3β and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?. Journal of Biological Chemistry 2001, 276:251-260.
19. Lin Y.K., Chang C.J., Chang Y.C., Wong W.R., Chang S.C., Pang J.H. Clinical assessment of patients with recalcitrant psoriasis in a randomized, observer-blind, vehicle-controlled trial using indigo naturalis. Archives of Dermatology 2008, 144:1457-1464.
20. Lin Y.K., Leu Y.L., Yang S.H., Chen H.W., Wang C.T., Pang J.H. Anti-psoriatic effects of indigo naturalis on the proliferation and differentiation of keratinocytes with indirubin as the active component. Journal of Dermatological Science 2009, 54:168-174.
21. Norrby K. In vivo models of angiogenesis. Journal of Cellular and Molecular Medicine 2006, 10:588-612.
22. Sethi G., Ahn K.S., Sandur S.K., Lin X., Chaturvedi M.M., Aggarwal B.B. Indirubin enhances tumor necrosis factor-induced apoptosis through modulation of nuclear factor-κB signaling pathway. Journal of Biological Chemistry 2006, 281:23425-23435.
23. Sugihara K., Kitamura S., Yamada T., Okayama T., Ohta S., Yamashita K., Yasuda M., Fujii-Kuriyama Y., Saeki K., Matsui S., Matsuda T. Aryl hydrocarbon receptor-mediated induction of microsomal drug-metabolizing enzyme activity by indirubin and indigo. Biochemical and Biophysical Research Communications 2004, 318:571-578.
24. Suzuki K., Adachi R., Hirayama A., Watanabe H., Otani S., Watanabe Y., Kasahara T. Indirubin, a Chinese anti-leukaemia drug, promotes neutrophilic differentiation of human myelocytic leukaemia HL-60 cells. British Journal of Haematology 2005, 130:681-690.
25. Timar J., Dome B. Antiangiogenic drugs and tyrosine kinases. Anti-Cancer Agents in Medicinal Chemistry 2008, 8:462-469.
26. Tran T.C., Sneed B., Haider J., Blavo D., White A., Aiyejorun T., Baranowski T.C., Rubinstein A.L., Doan T.N., Dingledine R., Sandberg E.M. Automated, quantitative screening assay for antiangiogenic compounds using transgenic zebrafish. Cancer Research 2007, 67:11386-11392.
27. Xiao Z., Wang Y., Lu L., Li Z., Peng Z., Han Z., Hao Y. Anti-angiogenesis effects of meisoindigo on chronic myelogenous leukemia in vitro. Leukemia Research 2006, 30:54-59.
28. Zhang Y., Lin Y., Bowles C., Wang F. Direct cell cycle regulation by the fibroblast growth factor receptor (FGFR) kinase through phosphorylation-dependent release of Cks1 from FGFR substrate 2. Journal of Biological Chemistry 2004, 279:55348-55354.
29. Zhen Y., Sorensen V., Jin Y., Suo Z., Wiedlocha A. Indirubin-3'-monoxime inhibits autophosphorylation of FGFR1 and stimulates ERK1/2 activity via p38 MAPK. Oncogene 2007, 26:6372-6385.
30. Zon L.I., Peterson R.T. In vivo drug discovery in the zebrafish. Nature Reviews Drug Discovery 2005, 4:35-44.